نتایج جستجو برای: daclatasvir

تعداد نتایج: 714  

2014
Do Young Kim Sang Hoon Ahn Kwang-Hyub Han

The combination of pegylated interferon (PEG-IFN) and ribavirin (RBV), the current therapy for hepatitis C virus (HCV) infection, has saved the lives of many HCV-infected patients. Direct-acting antivirals (DAAs) target several sites of HCV nonstructural proteins, resulting in the cessation of viral replication. The first NS3/4A protease inhibitors consisted of boceprevir and telaprevir, which ...

2016
Tatsuya Ide Yuichiro Eguchi Masaru Harada Kunihide Ishii Masaru Morita Yasuyo Morita Gen Sugiyama Hirofumi Fukushima Yoichi Yano Kazunori Noguchi Hiroki Nakamura Junjiro Hisatomi Hiroto Kumemura Miki Shirachi Shinji Iwane Michiaki Okada Yuichi Honma Teruko Arinaga-Hino Ichiro Miyajima Kei Ogata Reiichiro Kuwahara Keisuke Amano Toshihiro Kawaguchi Ryoko Kuromatsu Takuji Torimura

BACKGROUND The aim of this study was to evaluate the efficacy of daclatasvir plus asunaprevir therapy in patients infected with hepatitis C virus and determine its relevance to resistant variants. METHODS A total of 629 consecutive patients infected with hepatitis C virus genotype 1 were assessed. Daclatasvir (60 mg/day) plus asunaprevir (200 mg/day) was given for 24 weeks. The virological re...

2014
Hiromitsu Kumada Yoshiyuki Suzuki Kenji Ikeda Joji Toyota Yoshiyasu Karino Kazuaki Chayama Yoshiiku Kawakami Akio Ido Kazuhide Yamamoto Koichi Takaguchi Namiki Izumi Kazuhiko Koike Tetsuo Takehara Norifumi Kawada Michio Sata Hidetaka Miyagoshi Timothy Eley Fiona McPhee Andrew Damokosh Hiroki Ishikawa Eric Hughes

UNLABELLED All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin-based regimens. In this open-label, phase 3 study, 135 interferon-ineligible/intolerant and 87 nonresponder patients with chronic HCV genotype 1b infection were enrol...

Journal: :Gastroenterology clinics of North America 2015
Chalermrat Bunchorntavakul Tawesak Tanwandee

The management of hepatitis C virus (HCV) infection in special populations is challenging. The efficacy and safety data of the currently approved all-oral direct-acting antiviral combinations, including sofosbuvir, ledipasvir, daclatasvir, paritaprevir/ritonavir/ombitasvir plus dasabuvir (3D), and ribavirin, is compelling for use in special HCV populations, as has recently been recommended by e...

Journal: :Arquivos brasileiros de endocrinologia e metabologia 2011
Viroj Wiwanitkit

I read the recent report on body mass index and screening for cardiovascular disease risk with great interest (1). Bergmann and cols. concluded that “The BMI proposed in this study represents the more adequate alternative for screening school age children with increased chances of carrying DCV risk factors (1)”. Although I agree with this finding, I have some concerns about the study. First, th...

Journal: :Arquivos brasileiros de endocrinologia e metabologia 2011
Gabriel Gustavo Bergmann Adroaldo Gaya Ricardo Halpern Mauren Lúcia de Araújo Bergmann Ricardo Rodrigo Rech Cristine Boone Constanzi Lidiane Requia Alli

OBJECTIVE To purpose news body mass index (BMI) cut offs to 7 to 12 years old scholars. SUBJECTS AND METHODS 1.413 scholars of 7 to 12 years old selected of aleatory way. Were measured the BMI, total cholesterol (TC), and systolic (SBP) and diastolic blood pressure (DBP). To the date analyze were used the receiver operating characteristic curve (ROC curve) and the bivariate analyze. RESULTS...

2016
Sylvie Prud’homme Frederik Nevens Ingele Casteels

We report a patient with a bilateral optic anterior ischemic neuropathy as an extrahepatic complication of a chronic hepatitis C (HCV) infection. The patient presented with a bilateral visual acuity loss and bilateral optic disc oedema. The optic neuropathy was associated with a sudden increase in the viral HCV load after a recent liver transplantation. The stop of the calcineurin inhibitor had...

Journal: :Journal of Pakistan Medical Association 2023

Objective: To assess cardiovascular risk after sofosbuvir and daclatasvir antiviral combination therapy in chronic hepatitis C virus patients.Methods: The prospective cohort study was conducted at the Kafrelsheikh University Hospital, Egypt, from December 2019 to 2021, comprised adult patients of either gender with minimum ejection fraction 40%. They were classified into groups according their ...

Journal: :JAMA 2015
Fred Poordad William Sievert Lindsay Mollison Michael Bennett Edmund Tse Norbert Bräu James Levin Thomas Sepe Samuel S Lee Peter Angus Brian Conway Stanislas Pol Nathalie Boyer Jean-Pierre Bronowicki Ira Jacobson Andrew J Muir K Rajender Reddy Edward Tam Grisell Ortiz-Lasanta Victor de Lédinghen Mark Sulkowski Navdeep Boparai Fiona McPhee Eric Hughes E Scott Swenson Philip D Yin

IMPORTANCE The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. OBJECTIVE To determine the rates of sustained virologic response (SVR) in patients receiving the 3-drug combination of daclatasvir (a pan-genotypic NS5A inhibitor), asunaprevir (an NS3 protease inhibitor), and beclabuvi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید